Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06619860 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.

Recruiting
Registry status
Phase 2
Development phase
300
Enrollment target
20
Study locations

NCT06619860 is a Phase 2 study of Diabetic Peripheral Neuropathic Pain that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 300 participants, below the 394-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06619860, a Phase 2 study of Diabetic Peripheral Neuropathic Pain, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.

RECRUITING
Registry status
Phase 2
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Conditions Studied

Diabetic Peripheral Neuropathic Pain

Interventions

  • DRUG VX-993
  • DRUG Pregabalin
  • DRUG Placebo (matched to pregabalin)
  • DRUG Placebo (matched to VX-993)

Study Locations (20)

Florida

  • Accel Research - Deland - DeLand
  • AMR Fort Myers (The Clinical Study Center) - Fort Myers
  • Velocity Clinical Research - Hallandale Beach - Hallandale
  • Health Awareness, Inc., Jupiter - Jupiter
  • Suncoast Research Associates - Miami - Miami
  • Innovation Medical Research Center - Palmetto - Palmetto Bay
  • Health Awareness, Inc. - Port St. Lucie - Port Saint Lucie

California

  • Trovare Clinical Research - Bakersfield CA - Bakersfield
  • Eximia Research - San Diego - La Mesa

Georgia

  • Atlanta Center for Medical Research - Atlanta
  • Accel Research - Decatur - Decatur

Alabama

  • Cullman Clinical Trials - Cullman

Colorado

  • Paradigm Clincial Research Centers, LLC., Wheat Ridge - Wheat Ridge

Idaho

  • Velocity Clinical Research - Boise - Meridian

Illinois

  • Healthcare Research Network - Flossmoor IL - Flossmoor

Michigan

  • Quest Research Institute - Farmington Hills

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-10-18
Est. Completion 2026-05-30
Phase Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06619860

The ClinicalTrials.gov registry entry for NCT06619860 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (24% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 4 interventions - of which VX-993 is the first listed.

NCT06619860 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06619860 about?

NCT06619860 is a clinical study titled "Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy". The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

What is the current status of trial NCT06619860?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-10-18. Estimated completion is 2026-05-30.

What conditions does trial NCT06619860 study?

This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.

What interventions are being tested in trial NCT06619860?

The interventions under investigation include: VX-993 (DRUG), Pregabalin (DRUG), Placebo (matched to pregabalin) (DRUG), Placebo (matched to VX-993) (DRUG).

Who is sponsoring clinical trial NCT06619860?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06619860 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Peripheral Neuropathic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Peripheral Neuropathic Pain

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.